VBI Vaccines Inc. (NASDAQ: VBIV) is a biopharmaceutical company developing novel technologies that seek to expand vaccine protection in large underserved markets. VBI’s eVLP vaccine platform allows for the design of enveloped (“e”) virus-like particle (“VLP”) vaccines that closely mimic the target virus. The company’s lead eVLP asset is a prophylactic Cytomegalovirus (CMV) vaccine; VBI has initiated work for GMP manufacturing of its CMV candidate for use in formal preclinical and Phase I trials. The company’s second platform is a thermostable technology that enables the development of vaccines and biologics that can withstand storage or shipment at constantly fluctuating temperatures. VBI has completed proof of concept thermostability studies on a number of vaccine and biologic targets. VBI is headquartered in Cambridge, MA with research facilities in Ottawa, Canada. SNNLive spoke with Jeff Baxter from VBI Vaccines at the LD Micro "Main Event" 2014 in Bel Air, CA.
Mr. Baxter starts off with an overview of the company, "We're a newly listed NASDAQ company, fully listed on capital markets. We came to NASDAQ in late July, and we are a novel vaccine company that specializes in meeting unmet medical needs in significantly unmet vaccine markets."
“We have two platforms in the company, one that generates De-novo vaccines and our lead candidate is CMV. It’s for the prevention of congenital defects from CMV infection during pregnancy. It’s one of the – it is the largest cause of birth defects in the USA with over 40,000 impacted births per year and the other platform we have is one of the holy grails of vaccinology, which allows you to take vaccines out of the cold chain by formulating them for thermostability up to 40 degrees Celsius," he continues.
Mr. Baxter explains the dangers of CMV and what the vaccine has to offer, “CMV is particularly dangerous if a woman is exposed to CMV during the first trimester of her pregnancy, as I said it is the biggest cause of birth defects in the US at 40,000 a year. So CMV is a virus, which is fairly ubiquitous in the population, but the real issue becomes if a woman who is zero negative, that means not naturally immune to CMV becomes exposed to CMV and puts the unborn fetus at significant risk. This is a bigger form of birth defects then down-syndrome, fetal alcohol syndrome, and many of the other ones that are more well-known.” For more information, check out their website: www.VBIVaccines.com
Since speaking with VBI Vaccines, the company has made the following announcements:
© 2017 Stock News Now
Supported by Superior Web Solutions